‘Entire cell therapy sector’ realizes importance of supply chain management
The supply chain platform will manage WindMIL’s supply chain as it expands its involvement in clinical trials for its cell therapies. The platform will be live in over 100 sites globally and, according to the two companies. The site will aim to ‘harmonize’ all partner internal systems, as WindMIL expands its clinical trial footprint after a $32.5m (€28.45m) Series B fundraising.
WindMIL’s cell therapy pipeline, based on its expertise in bone marrow immunology, includes the only replicable and scalable process to create a cell therapy product from bone marrow-derived T cells.
This partnership is aimed increasing transparency of collection, transportation, and manufacturing through the supply chain during clinical trials.
Brian Halak, president and CEO of WindMIL said in a statement that this platform is important for its expansion into clinical trials as, “developing novel cellular therapies is also about logistics. It is important for us to ensure the supply chain works for each of the individuals involved in the patient’s care and for the oncology patients themselves.”
TrakCel’s CEO, Ravi Nalliah, added in a statement that the “entire cell therapy sector” is realizing the importance of supply chain tracking from an early stage. Due to this realization, the company is working with multiple companies in various stages of clinical development for supply chain management.
“The opportunity cost of the resources used for managing supply chains is even more important for companies at the earlier clinical stage. This means it is essential for TrakCel to continue to develop our cell therapy supply chain solutions as the cell therapy market continues to evolve,” Nalliah said.